Summary. Background: Activated protein C (APC) cell signaling is largely reliant upon its ability to mediate protease-activated receptor (PAR) 1 proteolysis when bound to the endothelial cell (EC) protein C (PC) receptor (EPCR). Furthermore, EPCR-bound PC modulates PAR1 signaling by thrombin to induce APC-like EC cytoprotection. Objective: The molecular determinants of EPCR-dependent cytoprotective PAR1 signaling remain poorly defined. To address this, a PC-factor VII chimera (PC ) possessing FVII N-terminal domains and conserved EPCR binding was characterized. Methods: Activated PC-FVII chimera (APC ) anticoagulant activity was measured with calibrated automated thrombography and activated FV degradation assays. APC signaling activity was characterized by the use of reporter assays of PAR1 proteolysis and EC barrier integrity. APC anti-inflammatory activity was assessed according to its inhibition of nuclear factor-jB (NF-jB) activation and cytokine secretion from monocytes. Results: PC was activated normally by thrombin on ECs, but was unable to inhibit plasma thrombin generation. Surprisingly, APC did not mediate EPCR-dependent PAR1 proteolysis, confer PAR1-dependent protection of thrombininduced EC barrier disruption, or limit PAR1-dependent attenuation of interleukin-6 release from lipopolysaccharide (LPS)-stimulated macrophages. Interestingly, EPCR occupation by active site-blocked APC was, like FVII, unable to mimic EC barrier stabilization induced by PC upon PAR1 proteolysis by thrombin. APC did, however, diminish LPS-induced NF-jB activation and
Introduction
The protein C (PC) pathway is a crucial regulator of blood coagulation and vascular inflammation. Thrombin binding to thrombomodulin (TM) activates PC [1] in a reaction that is further enhanced by concomitant binding of PC to the endothelial cell (EC) PC receptor (EPCR) [2] . Once generated, activated PC (APC) cleaves activated factor V (FVa) and activated FVIII to suppress thrombin generation [3] , degrades extracellular histones generated by tissue injury [4] , and activates protease-activated receptor (PAR) 1 to trigger cytoprotective signaling responses on ECs [5] . EPCR-dependent PAR1 signaling by APC confers EC barrier-protective, anti-inflammatory and antiapoptotic properties that ameliorate disease symptoms in preclinical disease models, including severe sepsis [6] , ischemic stroke [7] , and neurodegenerative disease [8, 9] . Despite its importance, the structural requirements necessary for EPCR-PAR1-APC signaling complex formation remain poorly defined.
In addition to signaling directly initiated by EPCR-bound APC proteolysis of PAR1, binding of PC/APC to EPCR also modulates thrombin signaling on ECs. In particular, when EPCR is 'occupied' by PC, thrombin-induced PAR1 signaling no longer promotes EC barrier disruption, but instead triggers APC-like EC barrier protection [10] . We and others have shown that both FVII and activated FVII (FVIIa) can also bind EPCR with high affinity by using the same binding motif as PC/APC [11] [12] [13] . Interestingly, however, binding of FVII(a) to EPCR does not modulate the effects of thrombin-induced EC barrier permeability [10] . The mechanistic basis for the differential effects of PC and FVII in regulating PAR1 signaling outcome when they occupy EPCR has not been defined.
In addition to the EPCR-PAR1 signaling axis, recent studies have shown that APC can induce cell signaling through alternative pathways in other cell types. For example, APC binding to the CD11b subunit of the CD11b-CD18 (Mac-1) integrin complex facilitates PAR1 proteolysis and anti-inflammatory signaling on macrophages. The importance of Mac-1-dependent PAR1 activation by APC is illustrated by the reduced capacity of APC to rescue CD11b À/À mice from lipopolysaccharide (LPS)-induced endotoxemia [14] . Moreover, several reports have indicated that APC utilizes different cell surface receptors to exert anticoagulant, anti-inflammatory and antiapoptotic effects on monocytes [15] [16] [17] . EPCR binding and PAR1 proteolysis are required for APC-induced secretion of the anti-inflammatory cytokine interleukin (IL)-10 from LPS-treated monocytes and reduction in camptothecininduced apoptosis in THP-1 monocytes [15, 16] . Furthermore, APC also binds apolipoprotein E receptor 2 (ApoER2) on U937 monocytes with approximately fivefold greater affinity than EPCR [17] . APC binding to ApoER2 triggers PAR1-independent phosphorylation of the adaptor protein disabled 1, Akt and glycogen synthase kinase-3b, which in turn promotes attenuation of LPSinduced tissue factor expression [17] . Both PC and FVII consist of an N-terminal c-carboxyglutamic acid (Gla) domain, two epidermal growth factor (EGF)-like domains, and a C-terminal protease domain [18, 19] . PC and FVII are subject to significant post-translational modifications, including c-carboxylation (9 Glu residues in PC; 10 in FVII) and N-linked glycosylation (PCAsn97, Asn248, Asn313, and Asn329; FVII -Asn145 and Asn322). FVII, but not PC, also has O-linked glycosylation and fucosylation sites within its first EGF domain [20] . PC and FVII share 54% amino acid sequence homology between their Gla and EGF1 domains, including an eightresidue insertion present in PC but not in FVII. To map novel molecular sites on APC that are important for specific signaling pathways, and to determine the mechanistic basis of PC-specific, EPCR-dependent cytoprotective PAR1 signaling by thrombin, a novel APC variant (APC ), in which the Gla and EGF1 domains of the FVII light chain were fused to the EGF2 and protease domains of APC, was generated. The presence of the FVII Gla domain enabled retention of EPCR affinity in the new variant, and permitted determination of whether APC-specific Gla/EGF1 domain residues outside the EPCR-binding motif also contribute to PAR1 signaling, or modulate cytoprotective PAR1 signaling by thrombin when bound to EPCR.
Materials and methods

Recombinant expression of PC FVII-82
Wild-type PC was expressed and purified as previously described [21, 22] . cDNA encoding PC FVII-82 was generated by de novo gene synthesis, and cloned into a pRC-CMV6 mammalian expression vector (Origene, Rockville, MD, USA), before stable transfection in HEK 293 cells was performed. Stably transfected HEK 293 cells were isolated by the use of G418 selection. Recombinant PC FVII-82 was isolated from the transfected cell supernatant with a combination of anion exchange chromatography and pseudo-affinity chromatography. Recombinant PC was quantified by PC ELISA (Quadratech, Surrey, UK), and then activated by thrombin and repurified, as previously described [21, 22] . Subsequent APC preparations were active site-titrated against known APC concentrations to confirm full activation and concentration, as previously described [21] . 2 , 0.6 mM MgCl 2 , and 1% (w/v) bovine serum albumin (BSA). PC activation was initiated by addition of thrombin (5 nM) to each well, followed by incubation at 37°C for 30 min. The reaction was then stopped with 135 nM hirudin (Sigma, Wicklow, Ireland). APC generation was determined by assessment of APC amidolytic activity in the cell supernatant, as previously described [22, 24] .
APC anticoagulant activity in platelet-poor plasma APC and APC anticoagulant functions in PC-deficient plasma were assessed with a Fluoroskan Ascent plate reader in combination with Thrombinoscope software (Thrombinoscope BV, Maastricht, the Netherlands), as previously described [22] . Briefly, 80 lL of plasma was incubated with 20 lL of platelet-poor plasma reagent (Thrombinoscope) containing 1 pM soluble tissue factor and 4 lm phospholipid vesicles (final concentrations) in the presence or absence of APC or APC FVII-82 (2.5-40 nM). Thrombin generation was initiated by dispensation of fluorogenic thrombin substrate and 100 mM CaCl 2 into each well. Thrombin generation was determined with Thrombinoscope software, as previously described.
Protein S-independent FVa degradation by APC FVa degradation by APC and APC was assessed as previously described [11] . APC (0.32 nM) was incubated at 37°C with phospholipid vesicles (phosphatidylcholine/ phosphatidylserine/phosphatidylethanolamine, 60% : 20% : 20%; Avanti Lipids, Alabaster, AL, USA) and 4 nM FVa (Haematologic Technologies, Essex Junction, VT, USA) in 40 mM Tris-HCl, 140 mM NaCl, 3 mM CaCl 2 , and 0.3% (w/v) BSA. At the specified time points, 2-lL aliquots were removed and added to a prothrombinase mixture (25 lM phospholipids, 1 nM activated FX, and 0.5 lM prothrombin (Haematologic Technologies, Essex Junction, VT, USA) for 3 min. Each reaction was then stopped with 5 lL of ice-cold 0.5 M EDTA. One hundred microliters of the reaction mixture was removed and incubated with 100 lL of 2 mM thrombin chromogenic substrate Biophen CS-01(38) (Hyphen-Biomed, Neuville-sur-Oise, France) to assess FVadependent prothrombinase activity.
Measurement of cell surface PAR1 proteolysis by APC
HEK 293T cells were seeded in 24-well microtiter plates until they were~80% confluent, and then transfected with plasmids encoding alkaline phosphatase (AP) -linked human PAR1 [25] and EPCR. Twenty-four hours later, transfected cells were washed with sterile phosphate-buffered saline (PBS) and treated with serum-free Dulbecco's modified Eagle's medium (DMEM) supplemented with 3 mM CaCl 2 and 0.6 mM MgCl 2 . Cells were incubated with APC or APC FVII-82 for 3 h, after which the supernatant was removed and AP activity measured by the use of QUANTI-Blue AP detection medium at 650 nm.
Assessment of APC protection of EC barrier permeability from thrombin-mediated disruption
The EC barrier-protective functions of APC and APC were assessed as previously described [21, 22, 26] . Briefly, EA.hy926 cells were seeded in transwell inserts, and then grown until confluent. EA.hy926 cells were then washed with sterile PBS and treated with serum-free DMEM supplemented with 3 mM CaCl 2 and 0.6 mM MgCl 2 . Cells were incubated with wild-type APC or APC FVII-82 for 3 h, and then treated with 5 nM thrombin for 10 min to induce barrier permeability. Cells were then washed again and incubated with Evans Blue/BSA. EC barrier permeability was determined by assessment of the increase in absorbance (A 650 nm ) in the outer chamber of the transwell insert over time. EC barrier permeability relative to cells treated with thrombin only was determined as before. In order to assess the barrier-protective capacity of EPCR-bound APC or APC in the presence of thrombin, active site-inhibited APC and APC were prepared by incubation with a 10-fold molar excess of FPR-chloromethylketone (PPACK) (Haematologic Technologies), and PPACK was then removed by the use of 7-kDa-cutoff Zeba desalt columns (Thermo, Waltham, MA, USA). EA.hy926 cells were grown to confluence on transwell inserts as before [21, 22] , and then preincubated with either PPACK-APC or PPACK-APC FVII-82 for 20 min to establish EPCR binding. After this incubation period, 5 nM thrombin was added to each well for a further 3 h to initiate PAR1 proteolysis [27] . At the end of this incubation period, the transwells were replaced with Evans Blue/BSA solution, and the barrier integrity of the treated ECs was determined by assessment of Evans Blue-BSA complex migration from the inner chamber of each transwell to the outer chamber, as previously described [21, 22, 26] .
Inhibition of proinflammatory cytokine secretion by LPSstimulated peripheral blood mononuclear cells (PBMCs) and murine macrophages PBMCs were isolated from buffy coat whole blood component obtained from healthy donors provided by the Irish Blood Transfusion Service, as previously described [27] . PBMCs were treated with APC or APC FVII-82 (both 20 nM) for 3 h, and then stimulated with LPS (50 ng mL À1 ) for 18 h. Tumor necrosis factor (TNF)-a secretion was measured by ELISA (R&D Systems, Minneapolis, MN, USA). Similarly, RAW264.7 macrophages were incubated with APC or APC FVII-82 (20 nM) for 3 h in HEPES buffer containing 3 mM CaCl 2 and 0.6 mM MgCl 2 prior to LPS stimulation (50 ng mL À1 ) for 18 h.
TNF-a secretion was measured by ELISA as previously described [21] .
Inhibition of NF-jB/activator protein-1 (AP-1) activation by APC in THP-1-XBlue-CD14 cells
To assess APC inhibition of LPS-induced NF-jB activation in human monocytes, NF-jB activity was measured by the use of THP-1 monocytic cells stably expressing an NF-jB/AP-1-inducible secreted AP reporter, with CD14 coexpressed to enhance sensitivity to LPS (Invivogen, Toulouse, France) [27] . THP-1-XBlue-CD14 cells were resuspended in serum-free RPMI-1640 medium supplemented with 0.6 mM CaCl 2 and 0.2 mM MgCl 2 at a density of 3 9 10 6 cells mL
À1
, and then seeded in 96-well microtiter plates. Cells were treated with APC or APC FVII-82 (0-20 nM) for 3 h, and then stimulated with LPS overnight (500 ng mL À1 ). AP activity in the supernatant arising from NF-jB activation was detected by the use of QUANTI-Blue medium containing AP substrate, with colorimetric measurements subsequently being made at 650 nm.
Results
Generation and characterization of APC FVII-82
To identify novel molecular determinants of cytoprotective PAR1 signaling by APC, a recombinant chimera was designed in which the PC Gla and EGF1 domains (residues 1-82) were exchanged with the corresponding domains of the homologous vitamin K-dependent protein FVII (PC FVII-82 ; Fig. 1A ,B). PC FVII-82 was expressed in stably transfected HEK 293 cells, and isolated and visualized by western blotting (Fig. 1C) . PC FVII-82 was detected as a doublet with a similar ratio of distinct a and b glycoforms as wild-type PC, with small quantities of singlechain wild-type PC and chimera also being observed. Recombinant PC was also sensitive to digestion by PNGase F (Fig. 1D) [21] . As expected, PC FVII-82 activated by thrombin showed similar amidolytic activity against a short chromogenic substrate to that of wild-type APC (data not shown).
PC N-terminal domain switching with FVII does not impair EPCR-enhanced or EPCR-independent PC activation by the thrombin-TM complex
To examine whether PC was also activated by thrombin on ECs, PC was incubated with EA.hy926 cells that express TM and EPCR in the presence of thrombin. PC FVII-82 was activated to a similar extent as wild-type PC, implying that interactions with EPCR and TM were not affected by the structural alterations present in PC FVII-82 ( Fig. 2A) (Fig. 2B) . Pertinently, EPCR enhancement of wild-type PC activation and EPCR enhancement of PC activation by the thrombin-TM complex were similar, indicating normal EPCR-dependent stimulation of PC activation by the thrombin-TM complex. To further characterize the PC FVII-82 interaction with EPCR, the ability of an active site-blocked APC FVII-82 to compete for EPCR binding was compared with FVII and an anti-EPCR antibody that blocks the PC-EPCR interaction (RCR-252). As expected, both FVII and RCR-252 attenuated PC activation by the thrombin-TM complex on ECs (Fig. 2C) . Interestingly, an equimolar concentration of active siteblocked APC FVII-82 also inhibited wild-type PC activation, suggesting that active site-blocked APC competes with PC to inhibit EPCR-enhanced PC activation by the thrombin-TM complex on the EC surface. Wild-type APC and APC FVII-82 were then assessed for their ability to inhibit tissue factor-initiated thrombin generation in platelet-poor PC-deficient plasma. Wild-type APC dose-dependently inhibited thrombin generation, with half-maximal inhibition occurring at < 2.5 nM APC (Fig. 3A,C) . In contrast, APC showed severely impaired anticoagulant activity, such that half-maximal inhibition was not achieved at the highest APC concentration tested (40 nM; Fig. 3B,C) .
To evaluate why APC FVII-82 showed impaired anticoagulant activity in plasma, the abilities of wild-type APC and APC to degrade FVa in a phospholipid-dependent manner were compared (Fig. 3D) . Interestingly, although APC FVII-82 showed a slightly reduced ability to degrade FVa as compared with wild-type APC, the reduction in FVa proteolytic activity was significantly less pronounced than the impaired anticoagulant activity observed previously in plasma. This suggests that, whereas APC FVII-82 interactions with FVa and anionic phospholipids remain largely intact, specific amino acid residues within the APC Gla and EGF1 domains, which are different from those necessary for phospholipid binding, are required for normal APC anticoagulant activity in platelet-poor plasma.
Defective EPCR-dependent PAR1 proteolysis and signaling by APC The ability of APC FVII-82 to mediate EPCR-dependent PAR1 proteolysis was then assessed, by use of a PAR1-AP reporter construct coexpressed with EPCR on the surfaces of transfected HEK 293T cells. Surprisingly, despite normal amidolytic activity and EPCR-dependent activation by the thrombin-TM complex, APC FVII-82 was unable to mediate EPCR-dependent PAR1 proteolysis (Fig. 4A) . Consequently, APC was also unable to confer EPCR-dependent and PAR1-dependent protection from thrombin-induced EC barrier disruption (Fig. 4B) , linking the defective PAR1 proteolysis by APC FVII-82 to diminished cytoprotective signaling functionality on ECs.
EPCR occupancy by PC/APC, but not FVII(a), is sufficient to reverse barrier-disruptive PAR1 signaling by thrombin [10] . To assess whether non-homologous amino acid residues between the PC and FVII Gla and EGF1 domains may account for their discrepant abilities to determine thrombin signaling outcome on ECs, active site-inhibited wild-type APC and APC FVII-82 were compared for their ability to mediate EPCR-dependent reversal of PAR1 signaling outcome when activated by thrombin [10] . As expected, preincubation with PPACKinhibited APC, which binds EPCR normally, caused thrombin signaling by PAR1 to promote EC barrier integrity (Fig. 4C) . In contrast, PPACK-inhibited APC FVII-82 was unable to modulate PAR1 signaling by thrombin (Fig. 4C) . These data suggest that non-homologous amino acid residues between the PC and FVII Gla and/or EGF1 domains are important for the ability of EPCR-bound PC to control PAR1 signaling outcome.
'Pathway-selective' signaling by APC FVII-82 on monocytes
To determine whether PAR1-independent APC FVII-82 cell signaling was also impaired, APC FVII-82 anti-inflammatory signaling via ApoER2 on monocytes was compared with Mac-1-dependent and PAR1-dependent signaling on RAW 264.7 macrophages. As with PAR1-dependent signaling on ECs, APC FVII-82 was unable to inhibit inflammatory cytokine release (IL-6) from LPS-stimulated RAW 264.7 macrophages in a PAR1-dependent manner (Fig. 5A) . In contrast, APC FVII-82 significantly diminished TNF-a release from both isolated PBMCs and monocytic THP-1 cells to a similar extent as wild-type APC (Fig. 5B,D) . Moreover, APC FVII-82 inhibited LPS-induced NF-jB activation on THP-1 NF-jB reporter cells as effectively as wild-type APC (Fig. 5C ). ApoER2-dependent anti-inflammatory signaling by APC on monocytic cells has been previously shown to require direct ApoER2 interaction to trigger downstream phosphoinositide 3-kinase (PI3K)-dependent pathway activation [17] . Accordingly, the anti-inflammatory activities of wild-type APC and APC , as measured by TNF-a secretion from LPS-stimulated THP-1 NF-jB reporter cells, were significantly inhibited by an anti-ApoER2 mAb and wortmannin, a small-molecule inhibitor of PI3K signaling (Fig. 5D) . Collectively, these data indicate that, despite defective anticoagulant and PAR1-dependent signaling functions on ECs and macrophages, APC FVII-82 remains competent for anti-inflammatory signaling on monocytes.
Discussion
APC must be bound to a coreceptor such as EPCR or Mac-1 to initiate PAR1 proteolysis. However, the additional interactions that must occur between APC and PAR1 for effective PAR1 proteolysis by APC remain largely undefined. Recent evidence suggests the importance of secondary exosite interactions between PAR1 and APC, distant from the APC active site, for effective PAR1 proteolysis. For example, a putative PAR1-binding exosite loop has been identified within the APC serine protease domain [28] . Specifically, recombinant APC variants possessing Ala substitutions at Glu330 and Glu333 are unable to mediate EPCR-dependent PAR1 proteolysis, and therefore do not protect the EC barrier from thrombin-mediated disruption or staurosporine-induced apoptosis [28] . Moreover, an APC variant (APC E149A ) that induces hyperactive anticoagulant activity also shows impaired EPCR-dependent cytoprotective PAR1 signaling. This illustrates the importance of Glu149 for PAR1 proteolysis by APC, although the precise role played by this amino acid residue in modulating multiple APC functions remains undetermined [29] .
In our study, APC FVII-82 was unable to mediate EPCRdependent PAR1 proteolysis in a heterologous cell expression system, and was unable to trigger EPCR-dependent PAR1 cytoprotective signaling on EA.hy926 cells. As the FVII Gla domain binds EPCR with similar affinity as PC/APC [11] , and shows identical EPCR-dependent activation by the thrombin-TM complex, the observed signaling defect does not appear to originate from diminished APC -EPCR binding. These data, in addition to the mildly impaired rate of FVa proteolysis in the absence of protein S shown by APC , suggest that the FVII Gla/EGF1 tandem domain substitution in APC FVII-82 does not induce global structural alterations within PC/APC FVII-82 that confer a broad loss of function, although crystallography or an alternative form of structural analysis would be required to evaluate whether unanticipated steric effects arising from the introduced FVII Gla and EGF1 domains contribute to the observed loss in PAR1 signaling function of APC . We also observed that APC anti-inflammatory activity on macrophages, which is dependent on Mac-1 interaction to facilitate PAR1 proteolysis [14] , was not triggered by APC , which failed to limit proinflammatory IL-6 secretion from LPS-exposed macrophages in a similar manner to wild-type APC. APC , however, retained selective anti-inflammatory ApoER2-dependent signaling activity on THP-1 monocytes and PBMCs, and effectively reduced NF-jB activation and TNF-a release to a similar extent as wild-type APC. Collectively, these data indicate that APC amino acid residues within the Gla and EGF1 domains that are not conserved with FVII are necessary for PAR1 proteolysis-dependent signaling. In contrast, these domain substitutions do not significantly impact on APC anti-inflammatory signaling triggered by ApoER2 binding on monocytes.
EPCR-bound PC switches the outcome of thrombin signaling on ECs such that barrier-disruptive PAR1 signaling is converted to APC-like EC barrier protection upon PAR1 activation [10] . The mechanistic basis for this functional reversal in PAR1 signaling outcome is not fully understood. Recent studies, however, have indicated that EPCR-bound PC prompts the recruitment of G-proteincoupled receptor kinase 5 to facilitate b-arrestin-2-dependent cytoprotective PAR1 signaling irrespective of PAR1 agonist and cleavage site [30] . FVIIa binds to EPCR with an identical binding motif to that of PC/APC and shows (both 50 nM) for 20 min, before thrombin (5 nM) incubation for 3 h, after which EC barrier permeability was assessed. Experiments were performed in triplicate, and data are presented as the mean AE standard deviation. *P < 0.05; **P < 0.01; ***P < 0.001. NS, not significant; PPACK, FPR-chloromethylketone. [Color figure can be viewed at wileyonlinelibrary.com]
identical EPCR-binding affinity [11] [12] [13] . EPCR-dependent PAR1 proteolysis and cytoprotective signaling by FVIIa have been reported, but appear to be dependent on the EC line used [10, 31, 32] . FVII-bound EPCR, however, has been consistently shown to be unable to mediate a similar switch to that of PC in reversing signaling outcome upon PAR1 proteolysis by thrombin on ECs [10, 33] . Consequently, APC FVII-82 served as a useful tool with which to determine whether additional PC/APC regions outside the EPCR-binding site might also contribute to this phenomenon. We found that active site-inhibited APC bound to EPCR was unable to trigger induction of cytoprotective PAR1 signaling by thrombin, mimicking EPCR-bound FVII(a) rather than APC, and, for the first time, identified amino acid residues within the PC/APC light chain that do not contact EPCR as being important in modulating the signaling outcome of PAR1 activation by thrombin. The functional disparity between EPCRbound APC and both FVII(a) and APC FVII-82 in modulating PAR1 signaling outcome may imply a role for specific PC/APC-specific light chain amino acid residues in binding PAR1 and modulating subsequent signaling outcome. Alternatively, PC/APC-specific light chain amino acid residues may be required for interaction with other EC surface receptors whose co-binding by APC may contribute to modulation of PAR1 signaling specificity. It is of note that ApoER2 has recently been demonstrated to contribute to EPCR-dependent and PAR1-dependent EC barrier protection by APC [34] . However, the ApoER2-binding site(s) on APC are currently unknown, and whether ApoER2 similarly contributes to EPCR occupancy-mediated reversal of PAR1 signaling outcome remains to be determined.
Interestingly, APC FVII-82 was also ineffective in mediating anticoagulant activity in platelet-poor plasma, requiring very large APC concentrations (> 40 nM) to confer a minor reduction in plasma thrombin generation. The ability of APC to mediate near-normal FVa proteolysis indicates that anticoagulant complex formation between APC FVII-82 , FVa and negatively charged phospholipid vesicles are largely unaffected by the domain substitutions in APC . Inhibition of thrombin generation in plasma by APC is largely dependent on a normal interaction with protein S at physiologically relevant APC concentrations, and a defective interaction between protein S and APC
FVII-82 appears to be the most likely source of impaired APC anticoagulant function, given previous data that support a critical role for the APC Gla and EGF1 domains in regulating APC anticoagulant activity. Specifically, APC amino acid substitutions within the Cterminal end of the APC Gla domain have been identified that render APC insensitive to protein S cofactor stimulation [11, 26] . Furthermore, an isolated APC light chain was found to inhibit APC anticoagulant activity in the presence of limiting protein S concentrations [35] . Despite this, the specific amino acid residues within the APC EGF1 domain that are necessary for protein S interaction and anticoagulant activity remain to be identified. APC FVII-82 therefore represents a novel tool with which to probe the downstream outcomes of APC-triggered ApoER2-dependent signaling on cell types such as ECs and monocytes, in which multiple potential APC receptors are expressed. By extension, APC FVII-82 may also have utility in defining the relative contribution of APC- NF-jB activities of LPS-stimulated THP-1-XBlue-CD14 cells were assessed in the presence of either APC (blue) or APC FVII-82 (red) when they were incubated with an anti-ApoER2 antibody (10 lg mL À1 ) or wortmannin (1 lM) for 3 h, and then stimulated with LPS (100 ng mL À1 mediated PAR1-independent ApoER2 signaling in conferring the therapeutic properties shown by APC in preclinical models of inflammatory disease, in which it has previously been shown to be beneficial. Collectively, the failure of APC FVII-82 to signal effectively on either ECs or macrophages identifies a novel role for APC-specific Gla/ EGF1 domain residues in enabling PAR1 proteolysis by APC and cytoprotective signaling by thrombin when PC occupies EPCR, without significantly impacting on ApoER2-dependent signaling by APC on monocytes. Addendum E. M. Gleeson and C. J. McDonnell performed experiments, analyzed data, conceived the study, and contributed to manuscript preparation. O. Willis Fox, H. Rushe, A. Rehill, O. P. Smith, J. S. O'Donnell, and E. E. Soule analyzed data and contributed to manuscript preparation. R. J. S. Preston performed experiments, analyzed data, conceived the study, and wrote the manuscript.
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